* concentrated Tylenol(R) Infants' Drops Plus Cold
* concentrated Tylenol(R) Infants' Drops Plus Cold and cough
* PediaCare(R) Infant Drops products
FORT WASHINGTON, Pa., Oct. 11 /PRNewswire/ -- McNeil Consumer Healthcare, a division of McNeil-PPC, Inc., announced today that the company is voluntarily withdrawing certain infants' cough and cold products from the market. When used as directed, these medicines are generally recognized as safe and effective. While most parents use these medicines appropriately and follow dosing directions, an assessment of available data on the use of pediatric cough and cold medicines has identified rare instances of misuse leading to overdose, particularly in infants under 2 years of age.
McNeil Consumer Healthcare is withdrawing Concentrated Infants' TYLENOL(R) Drops Plus Cold; Concentrated Infants' TYLENOL(R) Drops Plus Cold & Cough; PEDIACARE(R) Infant Drops Decongestant (PSE); PEDIACARE(R) Infant Drops Decongestant & Cough (PSE); PEDIACARE(R) Infant Dropper Decongestant (PE); PEDIACARE(R) Infant Dropper Long-Acting Cough; and PEDIACARE(R) Infant Dropper Decongestant & Cough (PE) products from the U.S. market.
Cough and cold products for children age two and over and single- ingredient pain reliever/fever reducers expressly labeled for infants are not included in this voluntary withdrawal and remain available for parents and caregivers.
"This voluntary action by McNeil Consumer Healthcare is based on the
company's long-standing commitment to the appropriate use of medications by
parents and physicians," said Ashley McEvoy, President, McNeil Consumer
Healthcare. "McNeil Consumer Healthcare is committed to providing parents
with safe and effective over-the-counter medications that treat their
child's cough and cold symptoms. In addition to taking this voluntary
action, McNeil Consumer Healthcare, along with our industry partners,
supports the Consumer Healthcar
|SOURCE McNeil Consumer Healthcare|
Copyright©2007 PR Newswire.
All rights reserved